Montek (Sodium Molybdate (99mo))

Sodium molybdate, the active ingredient in Montek, is a molybdenum compound presented as a sterile solution for intravenous and ocular use. It is employed primarily as a diagnostic adjunct in clinical procedures that require molybdenum‑based radiopharmaceuticals or ocular diagnostic solutions.

GNH USA supplies Montek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Montek (sodium molybdate) is used primarily as a diagnostic adjunct in procedures involving intravenous or ocular administration.

Diagnostic imaging preparation: provides molybdenum‑99 precursor for technetium‑99m generator systems. Molybdenum deficiency correction: used to restore normal molybdenum levels in patients with confirmed deficiency. Ophthalmic diagnostic solutions: incorporated into certain ocular formulations for diagnostic testing.

Common Side Effects: - Nausea or vomiting - Headache or mild dizziness - Injection site pain or erythema - Metallic taste in the mouth - Transient flushing or mild hypotension - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Anaphylactic reaction or severe allergic response - Significant hypotension requiring medical intervention - Acute renal impairment or failure - Hepatic dysfunction with elevated enzymes - Hemolysis or severe hemolytic anemia - Life‑threatening bronchospasm

Precautions should be observed when Montek is administered to ensure patient safety.

Renal function: assess baseline renal status and monitor during therapy. Hypersensitivity: avoid use in patients with known allergy to molybdenum compounds. Pregnancy: limit use to situations where benefits outweigh potential risks. Concurrent metal supplements: high‑dose iron or copper may interfere with molybdate absorption. Monitoring: observe vital signs and infusion site throughout administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Montek may interact with other medicines; awareness of these interactions helps mitigate risk.

Major Interactions (Avoid): - Chelating agents (e.g., EDTA): bind molybdate and reduce efficacy. - High‑dose iron supplements: compete for absorption pathways. - Nephrotoxic drugs (e.g., aminoglycosides): increase risk of renal injury.

Moderate Interactions (Monitor Closely): - Antihypertensives: may potentiate hypotensive effects. - Diuretics: can alter electrolyte balance when combined. - Other molybdenum‑containing compounds: additive toxicity potential.